-
-
-
-
-
-
-
Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology
-
-
-
-
-
-
-
Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
-
-
-
-
-
-
-
Foamix (FOMX) Announces Additional Positive Topline Results from Third Phase 3 Trial Evaluating FMX101
-
-
-
-
-
-
-
Foamix (FOMX) Says Third Phase 3 Trial of FMX101 for Acne Met Co-primary Endpoints
-
-
-
-
-
-
-
Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103
-
-
-
-
-
-
-
Foamix (FOMX) Reports Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year
-
-
-
-
-
-
-
Foamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for August 9
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

